Drucker, DJ, GLP-1-based therapies for diabetes, obesity and beyond. Nat Rev Drug Discov, 2025 published online April 25. https://doi.org/10.1038/s41573-025-01183-8.
Douros, JD, Mokrosinski, J, Finan, B, The GLP-1R as a model for understanding and exploiting biased agonism in next-generation medicines. J Endocrinol, 261, 2024, e230226.
El Eid, L, Reynolds, CA, Tomas, A, et al. Biased agonism and polymorphic variation at the GLP-1 receptor: implications for the development of personalised therapeutics. Pharmacol Res, 184, 2022, 106411.
Tan, TM-M, Is biased agonism helpful in the treatment of obesity with the GLP-1 receptor analogues?. Lancet Diabetes Endocrinol 13 (2025), 728–730.
Ji, L, Gao, L, Xue, H, et al. Efficacy and safety of a biased GLP-1 receptor agonist ecnoglutide in adults with overweight or obesity: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Diabetes Endocrinol 13 (2025), 777–789.
Zhu, D, Wang, W, Tong, G, et al. Efficacy and safety of GLP-1 analog ecnoglutide in adults with type 2 diabetes: a randomized, double-blind, placebo-controlled phase 2 trial. Nat Commun, 15, 2024, 8408.
He, Y, Mi, N, Cheng, Z, et al. Efficacy and safety of cAMP-biased GLP-1 receptor agonist ecnoglutide versus dulaglutide in patients with type 2 diabetes and elevated glucose concentrations on metformin monotherapy (EECOH-2): a 52-week, multicentre, open-label, non-inferiority, randomised, phase 3 trial. Lancet Diabetes Endocrinol, 2025 published online Aug 22. https://doi.org/10.1016/S2213-8587(25)00196-2.
Jones, B, The therapeutic potential of GLP-1 receptor biased agonism. Br J Pharmacol 179 (2022), 492–510.
Rosenstock, J, Hsia, S, Nevarez Ruiz, L, et al. Orforglipron, an oral small-molecule GLP-1 receptor agonist, in early type 2 diabetes. N Engl J Med, 2025 published online June 21. https://doi.org/10.1056/NEJMoa2505669.
